Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

warszawskie zaklady farmaceutyczne polfa s.a. - salbutamol - 14 - bronchodilatantia, antiasthmatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

warszawskie zaklady farmaceutyczne polfa s.a., poľsko - salbutamol - 14 - bronchodilatantia, antiasthmatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline (ireland) limited, Írsko - salbutamol - 14 - bronchodilatantia, antiasthmatica

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

le vet beheer, holandsko - sirup

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

boehringer ingelheim vetmedica, srn - gran.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ursapharm arzneimittel gmbh, nemecko - umelé slzy a iné indiferentné liečivá - 64 - ophthalmologica

Európska únia - slovenčina - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals pre felidae, - mačky - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. imunosupresia bola preukázaná 1 týždeň po primárnom očkovaní proti rhinotracheitíde, kalicivírusu a zložkám chlamydophila felis. trvanie imunity je 1 rok po poslednej (opätovnej) vakcinácii.

Európska únia - slovenčina - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinóm, šquamózna bunka - antineoplastické činidlá - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Európska únia - slovenčina - EMA (European Medicines Agency)

merck europe b.v. - avelumab - neuroendokrinné nádory - iné antineoplastické činidlá, monoklonálne protilátky, - bavencio je označené ako monotherapy na liečbu dospelých pacientov s metastatickým merkelová bunky karcinómu (mkc). bavencio v kombinácii s axitinib je uvedené, za prvé-line liečbu dospelých pacientov s pokročilým karcinómom obličiek (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.